Anastrozole Tablet
Product Images NDC 68071-3999

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 68071-3999). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3999 3)

This text contains information about Anastrozole tablets, with a strength of 1mg per tablet, packaged in a bottle of 30 tablets. It provides details such as the NDC number, expiration date, serialization number, and storage instructions. The product is from NuCare Pharmaceuticals, Inc.*

FDA Label Image

7b4ba0c5 0287 B7a7 E053 2991aa0a575e

FDA Label Image

Avet Logo (Avet)

FDA Label Image

Chemical Structure For Anastrozole (Image 01)

FDA Label Image

Figure 1 (Image 02)

This data presents a comparison between the disease-free survival rates of patients treated with anastrozole and tamoxifen over a 90-month period. The number of patients at risk for each treatment group is provided at various time intervals. This information can be used to analyze and compare the effectiveness of the two treatments in terms of disease-free survival.*

FDA Label Image

Figure 2 (Image 03)

The data provided shows disease-free survival in months for two types of treatments - anastrozole and tamoxifen. The number of patients at risk is also displayed for each time point. The graph or chart may show a comparison of the survival rates between the two treatments over time.*

FDA Label Image

Figure 3 (Image 04)

This document appears to be a graph displaying survival rates or event occurrence over time for patients under randomized treatment with two different medications, Anastrozole and Tamoxifen. The x-axis represents time in months, while the y-axis likely indicates the proportion or number of patients remaining. The graph shows the number of patients at risk at different time points for each treatment group. It is noted that the vertical axis has been truncated to enhance clarity in the Kaplan-Meier curves.*

FDA Label Image

Figure 4 (Image 05)

This text appears to be a data chart showing the comparison of randomized treatment between Anastrozole and Tamoxifen over time. The chart includes the number of patients at risk at different months. The vertical axis has been truncated for better clarity of the Kaplan-Meier curves.*

FDA Label Image

Figure 5 (Image 06)

FDA Label Image

Figure 6 (Image 07)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.